BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 30c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.66), $0.30 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $54.02 million versus the consensus estimate of $29.12 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform